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Cryptosporidium hominisCryptosporidiosis, a gastrointestinal disease caused by a protozoan Cryptosporidium hominis is often fatal
in immunocompromised individuals. There is little clinical data to show that the existing treatment by
nitazoxanide and paromomycin is effective in immunocompromised individuals.1,2 Thymidylate syn-
thase (TS) and dihydrofolate reductase (DHFR) are essential enzymes in the folate biosynthesis pathway
and are well established as drug targets in cancer and malaria. A novel series of classical antifolates, 2-
amino-4-oxo-5-substituted pyrrolo[2,3-d]pyrimidines have been evaluated as Cryptosporidium hominis
thymidylate synthase (ChTS) inhibitors. Crystal structure in complex with the most potent compound,
a 20-chlorophenyl with a sulfur bridge with a Ki of 8.83 ± 0.67 nM is discussed in terms of several Van
der Waals, hydrophobic and hydrogen bond interactions with the protein residues and the substrate ana-
log 5-ﬂuorodeoxyuridine monophosphate. Of these interactions, two interactions with the non-con-
served residues (A287 and S290) offer an opportunity to develop ChTS speciﬁc inhibitors. Compound 6
serves as a lead compound for analog design and its crystal structure provides clues for the design of ChTS
speciﬁc inhibitors.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Cryptosporidiosis is a gastrointestinal disease caused by a pro-
tozoan Cryptosporidium hominis (Ch). This infectious disease causes
gastrointestinal distress in immunocompetent individuals and is
often fatal in immunocompromised individuals such as patients
with AIDS, cancer and those who have had organ transplants. There
are no effective, approved therapies to treat cryptosporidiosis to
date. There is little effort by the pharmaceutical industry in drug
development against this disease. The existing treatment includes
nitazoxanide and paromomycin. However, there is little clinical
data to show that these drugs are effective especially in immuno-
compromised individuals.1,2 Thus, there is a medical need for dis-
covery of new antiparasitic drugs. Thymidylate synthase (TS) and
dihydrofolate reductase (DHFR) are essential enzymes in the folate
biosynthesis pathway and are well established as drug targets incancer and malaria. TS catalyzes the reaction of deoxyuridine
monophosphate (dUMP) and methylene tetrahydrofolate (CH2H4F)
to yield deoxythymidine monophosphate (dTMP) and dihydrofo-
late (H2F). DHFR catalyzes the reduction of H2F, in the presence
of nicotinamide adenine dinucleotide phosphate (NADPH), to gen-
erate tetrahydrofolate (H4F). In C. hominis these enzymes are
bifunctional and exist on a single polypeptide chain. The successful
development of inhibitors targeting DHFR3–5 from Plasmodium
falciparum, Trypanosoma Cruzi, C. hominis3–5 have been well docu-
mented in the literature. While there are many TS inhibitors being
developed as anticancer agents,6 there are fewer developments
towards inhibitors targeting TS from parasites. The successful
development of potent and selective inhibitors of DHFR for para-
sites and bacteria encourages the development of species-speciﬁc
TS inhibitors. A potent TS inhibitor can be administered with a po-
tent DHFR inhibitor as a combination therapy targeting pathogenic
parasites. In this study we present a novel series of classical antif-
olates, 2-amino-4-oxo-5-substituted pyrrolo[2,3-d]pyrimidines
with variation in the chain length (1–4) and the side chain phenyl
to a thiophene (5) and a 20-chlorophenyl with a sulfur rather than a
carbon bridge (6) as ChTS inhibitors and evaluate these compounds
for inhibition of ChTS enzyme activity. We also report the crystal
structure of our leading TS inhibitor in complex with ChTS-DHFR.
Figure 1. Structures of compounds 1–6 with their ChTS IC50 values shown as the
bar graph.
Figure 2. Stereo view of a 2Fo–Fc electron density map (contour level at 1.0 r) for TS
active site of ChTS-DHFR:FdUMP:compound 6 complex.
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active site residues can be utilized to develop potent and selective
parasite speciﬁc TS inhibitor.
Gangjee et al. reported the synthesis of compounds 1–47 as well
as compound 6.8 Our modiﬁcation for the synthesis of compound 5
is reported in Scheme 1.
a-Bromination of the aldehyde 79 (Scheme 1) with 5,5-dibro-
mo-2,2-dimethyl-4,6-dioxo-1,3-dioxane 8 at room temperature
afforded the corresponding a-bromo aldehyde 9. Intermediate 11
was obtained by condensation of 9with 10 at 45 C in the presence
of sodium acetate. Hydrolysis with 3 N NaOH and coupling with
diethyl L-glutamate using N-methyl morpholine and 2,4-dime-
thoxy-6-chlorotriazine as the activating agents afforded the diester
12 (yield: 70% over two steps). Saponiﬁcation of the diester with
1 N NaOH gave 5.
IC50 values for the compounds 1–6 in an in vitro ChTS enzyme
assays range between 0.01 and 31 lM (Fig. 1 and Table S1). Inhi-
bition data suggests that potency of the pyrrolo[2,3-d]pyrimidines
is linked to the length and composition of the linker connecting
the pyrrolo[2,3-d]pyrimidine scaffold to the glutamate tail. Com-
pound 1 with a one carbon linker has the lowest IC50 (0.38 lM),
while IC50 values for compounds 2–4 with increasing length of
linkers are higher. Substitution of the side-chain phenyl ring of
1 with an isosteric thiophene in 5 increases potency by 10-fold
to IC50 = 0.03 lM. Addition of a 6-methyl and an electron with-
drawing 20-Cl on the phenyl ring of 1 affords increased potency
of 38-fold over 1 to the most potent analog of the series, 6. Com-
pounds 5 and 6 with an aromatic ring in the linker show much
higher potency.
Compound 6 was further characterized as a tight binding inhib-
itor with Ki of 8.83 ± 0.67 nM. IC50 values for human TS enzyme are
similar to the ones obtained for ChTS and inhibition of ChDHFR
shows a similar trend in which the IC50 values increase with linker
length, a side chain thiophene and a 6-methyl-20-Cl phenyl (data
not shown).
The most potent ChTS inhibitor compound 6was co-crystallized
along with other three ligands (5-ﬂuorodeoxyuridine monophos-
phate (FdUMP), NADPH and methotrexate (MTX)) and ChTS-DHFR.
Detailed crystallization conditions have been reported in the Sup-
plementary data. The best crystals diffracted to amplitudes extend-
ing to a resolution of 3.08 Å (Table S2). Phases were solved via
molecular replacement using the program Phaser. The search mod-
el used for molecular replacement was the ChTS-DHFR structure in
complex with four ligands (CB3717 and deoxyuridine monophos-
phate at TS site and NADPH and MTX at DHFR site) (PDB code:
1QZF). Root Mean Square deviation (RMSD) between 1QZF and
our structure is 0.751 Å (for an all atom alignment) suggesting that
the overall conformation of the protein is similar (Fig. S1). All res-
idues from 3 to 521 except for residues 179–192 are clearly deﬁned
in the electron density, allowing all of the ligand binding sites of
the structure to be visualized (Fig. S2).yield: 57%
SO
O
CHO
Br
O
O
O
O
Br
Br
HCl, r.t.
8
9
HN
N
O
H2N NH2
10
yield: 59%
HN
N NH
O
H2N
O
S
O
11
MeOH, 45°C
CH3COONa
yield: 70%
HN
N NH
O
H2N
H
N
O
COOEt
COOEt
Si) 3N NaOH
ii) NMM, r.t.
2,4-dimethoxy-6-
chloro-triazine,
diethyl-L-glutamate
1N NaOH, r.t.
yield: 93%
HN
N NH
O
H2N
H
N
O
COOH
COOH
S
12 5
SO
O
CHO
7
Scheme 1.Figure 2 shows a stereo view of a 2Fo–Fc electron density map of
the active site region to illustrate the positions of the FdUMP and
compound 6 complex.
There are several Van der Waals and hydrophobic interactions
between compound 6 and ChTS (Fig. 3) with residues I315, W316
and F433 on one side of the molecule, L399, Y466, L429, M519
on the other side and A287 at the glutamate tail of compound 6.Figure 3. Stereo view of the active site residues and FdUMP interacting with
compound 6. Hydrogen bonds (3.5 Å or less) are shown as dashed lines.
Figure 4. An all atom alignment of ChTS-DHFR:compound 6 (green:purple) and
human TS (tan, PDB code: 1HVY). RMSD = 0.77 Å.
5428 V. P. Kumar et al. / Bioorg. Med. Chem. Lett. 23 (2013) 5426–5428The sulfur atom of M519 is positioned to interact with N1 as well
as 20-Cl on the phenyl ring of compound 6. The ﬂuorine of FdUMP
makes an additional electrostatic contact with hydroxyl of Y342 as
well as a non-covalent interaction with sulfur atom of compound
6.10
The pyrimidine ring of FdUMP has a stacking interaction with
thepyrrolo[2,3-d]pyrimidine scaffold of compound 6. In addition
to several Van der Waals and hydrophobic interactions, compound
6 is involved in hydrogen bonding interactions with FdUMP and
active site residues. The O2 atom on the ribose ring of FdUMP is
hydrogen bonded with N1 and N3 of compound 6.
Carbonyl O of D426 hydrogen bonds (3 Å) with N3 and carbonyl
O of N319 hydrogen bonds with N7 of compound 6 (2.9 Å). The 4-
oxo group of compound 6 interacts with the amino group of G430.
Hydrogen bonding interactions between the hydroxyl of Y466 and
carbonyl O of A520 with the 2-amino group of compound 6 must
add to its binding into the active site. The ChTS active site has
two unique residues, A287 and S290. These residues have been
shown to be important for optimal positioning of the cofactor CH2-
H4F and catalysis.11 In human TS, the corresponding residues are
F80 and G83 (Fig. 4). This structural difference can be exploited
to design parasite speciﬁc potent TS inhibitors by substituting suit-
able groups to make the binding of inhibitor favorable to ChTS.
In summary, a series of pyrrolo[2,3-d]pyrimidines are identiﬁed
as ChTS inhibitors. A direct correlation between inhibition of ChTSenzyme and length of the linker connecting the glutamate tail was
established. Shorter alkyl linkers afford better potency. Having aro-
matic ring structures in the linker provide additional interactions
with the active site residues resulting in increased potency of the
compound 6 with a Ki of 8.83 ± 0.67 nM. Several hydrophobic,
Van der Waals and hydrogen bonding interactions were observed
between compound 6 and FdUMP; compound 6 and active site
residues.
Of these interactions, two are unique as these residues (A287
and S290) are non-conserved residues of ChTS. Interactions with
these residues offer an opportunity to develop ChTS speciﬁc
inhibitors by exploiting the presence of bulky phenylalanine in
human TS and an additional hydrogen bond donor with S290 in
ChTS as compared with a glycine in human TS. For effective ther-
apy for cryptosporidiosis, especially in immunocompromised
individuals, a combination therapy of a potent parasite speciﬁc
TS inhibitor with a potent DHFR inhibitor can be administered.
Compound 6 serves as a lead compound for analog design and
its crystal structure provides clues for the design of ChTS speciﬁc
inhibitors.
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